Investigating how certain enzymes affect cancer treatment
How ubiquitin-carrying enzymes contribute to ubiquitin ligase specificity
['FUNDING_R01'] · UNIVERSITY OF NEVADA LAS VEGAS · NIH-10799575
This study is looking at how certain enzymes help break down proteins in the body, which could lead to new ways to treat cancers like breast cancer by making it easier to target tough-to-treat proteins, ultimately aiming to improve cancer therapies for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEVADA LAS VEGAS (nih funded) |
| Locations | 1 site (LAS VEGAS, UNITED STATES) |
| Trial ID | NIH-10799575 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of ubiquitin-carrying enzymes, specifically Cullin-RING ligases, in regulating protein degradation, which is crucial for treating various cancers, including breast cancer. By exploring how these enzymes can be manipulated to target disease-causing proteins, the research aims to develop new therapeutic strategies that could make previously undruggable proteins susceptible to treatment. Patients may benefit from advancements in drug development that utilize these findings to improve cancer therapies. The approach involves biochemical assays and molecular biology techniques to elucidate the mechanisms of enzyme regulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer or other malignancies that may benefit from novel therapeutic strategies targeting protein degradation.
Not a fit: Patients with conditions unrelated to the mechanisms of ubiquitin ligases or those who do not have malignancies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new cancer treatments that effectively target and degrade harmful proteins in patients.
How similar studies have performed: Other research has shown promising results in targeting ubiquitin ligases for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
LAS VEGAS, UNITED STATES
- UNIVERSITY OF NEVADA LAS VEGAS — LAS VEGAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KLEIGER, GARY L. — UNIVERSITY OF NEVADA LAS VEGAS
- Study coordinator: KLEIGER, GARY L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers